Encompass Health (NYSE:EHC) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 9.9% year on year to $1.54 billion. The company’s non-GAAP profit of $1.46 per share was 12.1% above analysts’ consensus estimates. Encompass Health’s adjusted EBITDA for the quarter was $335.6 million, beating analyst estimates by 7%. The company’s annualized revenue growth over the last two years was 11.2%, showing positive performance. Encompass Health’s adjusted operating margin has increased by 1.8 percentage points over the last two years. The company’s EPS grew at a compounded annual growth rate of 13.6% over the last five years.

Read more at Barchart: Encompass Health (NYSE:EHC) Reports Q4 CY2025 In Line With Expectations, Stock Jumps 17.5%